Skip to main content
syn
Daily Digest
Science & Health

FDA approves world's first mRNA flu vaccine

Published Monday, June 22, 2026 · Updated June 22

Share on X

Narrative Spectrum

Convergent Narrative · 0
  • FDA Vaccine Recommendation — 1 source

Media Analysis

AI synthesis

The FDA's advisory committee has unanimously recommended the approval of Moderna's mRNA-based flu vaccine, mFlusiva, for individuals aged 50 and older. Clinical trials indicated that mFlusiva was approximately 27% more effective than traditional flu shots.

What We Know — Key Points

  • Moderna's mFlusiva vaccine was found to be about 27% more effective than a standard flu shot in a late-stage trial.
  • The FDA's advisory committee unanimously recommended approving Moderna's mRNA-based flu vaccine, mFlusiva, for people 50 and older.

What Is Claimed — Perspectives

FDA Vaccine Recommendation
  • The Jerusalem Post

    The FDA's advisory committee unanimously recommended approving Moderna's mRNA-based flu vaccine, mFlusiva, for people 50 and older. This vaccine, found to be 27% more effective than standard shots in trials, marks a significant advancement in illness prevention.

AI-Generated Content

  • This topic was generated by an AI system.
  • Key points, perspectives, bias labels, and categorisation may contain errors.
  • This is not journalism. Do not rely on this content for critical decisions.
  • Read our full AI disclaimer for details.